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Runx1-deficient mice die around embryonic day 11.5 due to impaired hematopoiesis. This early death prevents the analysis of the role of
Runx1 in the development of sensory ganglia. To overcome the early embryonic lethality, we adopted a new approach to utilize transgenic Runx1-
deficient mice in which hematopoietic cells are selectively rescued by Runx1 expression under the control of GATA-1 promoter. In Runx1-
deficient mice, the total number of dorsal root ganglion (DRG) neurons was increased, probably because of an increased proliferative activity of
DRG progenitor cells and decreased apoptosis. In the mutant DRG, TrkA-positive neurons and peptidergic neurons were increased, while c-ret-
positive neurons were decreased. Axonal projections were also altered, in that both central and peripheral projections of CGRP-positive axons
were increased. In the dorsal horn of the spinal cord, projections of CGRP-positive axons expanded to the deeper layer, IIi, from the normal
terminal area, I/IIo. Our results suggest that Runx1 is involved in the cell fate specification of cutaneous neurons, as well as their projections to
central and peripheral targets.
© 2006 Elsevier Inc. All rights reserved.Keywords: Runx; Transcription factor; Knockout mouse; Dorsal root ganglion; CGRP; Spinal cord; TrkA; c-ret; Cell-type specification; Axonal projectionIntroduction
Runt-related (Runx) genes encode the DNA-binding α-
subunit of the Runt domain transcription factor, polyomavirus
enhancer-binding protein 2 (PEBP2)/core-binding factor
(CBF). The Runt-related transcription factors are phyloge-
netically conserved and play important roles in embryogenesis
(for a review, see Coffman, 2003). In Drosophila, the runt gene
regulates various developmental processes including segmen-
tation and neuronal differentiation (Dormand and Brand, 1998;
Duffy et al., 1991). In mammals, there are three members of
Runx family transcription factors: Runx1, 2 and 3 (Ito, 2004).
These transcription factors play critical roles in the development
of various cell types from endodermal, mesodermal and
ectodermal origin, and mutations in these transcription factors
are closely related to specific diseases (De Brujin and Speck,⁎ Corresponding author. Fax: +81 29 853 6960.
E-mail address: tshiga@md.tsukuba.ac.jp (T. Shiga).
0012-1606/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2006.12.0072004; Stein et al., 2004; Suk-Chul and Joong-Kook, 2004).
From these studies, it was determined that Runx1 regulates the
differentiation of hematopoietic cells in the fetal liver and its
mutation is closely associated with human acute myeloid
leukemia. In addition, Runx2 regulates the differentiation of
osteoblasts and is associated with cleidocranial dysplasia.
Finally, Runx3 regulates the proliferation and survival of
gastric epithelial cells and is related to gastric cancer.
Recent studies have shown that Runx1 and Runx3 are also
expressed in specific subtypes of neurons in the peripheral and
central nervous systems (Inoue et al., 2002; Levanon et al.,
2001; Simeone et al., 1995; Theriault et al., 2004). In the dorsal
root ganglion (DRG), Runx1 and Runx3 are expressed in the
TrkA-expressing (TrkA+) cutaneous neurons and TrkC-expres-
sing (TrkC+) proprioceptive neurons, respectively (Chen et al.,
2006a,b; Kramer et al., 2006; Levanon et al., 2001; Marmigere
et al., 2006). This cell-type-specific expression of Runx1 and
Runx3 prompted the functional analyses of these transcription
factors, which revealed their involvement in various processes
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neurons are maintained in Runx3-deficient (Runx3−/−) mice, but
the axonal projection of proprioceptive DRG neurons to both
central and peripheral targets is severely impaired (Inoue et al.,
2002). Another study reported that proprioceptive DRG
neurons lose their selective phenotypic markers, including
TrkC, in the Runx3−/− mice (Levanon et al., 2002). Further-
more, recent studies demonstrated that Runx3 plays pivotal
roles in the cell type specification of proprioceptive DRG
neurons and the elaboration of their central projection to the
spinal cord (Chen et al., 2006a; Kramer et al., 2006).
In contrast to Runx3, a functional analysis of Runx1 in neural
development was delayed because a deficiency of Runx1 results
in lethality around embryonic day (E) 11.5 due to the impaired
fetal liver hematopoiesis (Okuda et al., 1996; Theriault et al.,
2004, 2005; Wang et al., 1996). To overcome this limitation
caused by the early embryonic lethality, Chen et al. (2006b)
utilized a conditional gene targeting technique and showed that
Runx1 is required for the proper cell specification and axonal
projection of nociceptive DRG neurons. Although much progress
has been made in the functional analysis of Runx1 in the neural
development, there seems to be several discrepancies among
previous studies concerning cell fate specification and axonal
projections (Chen et al., 2006a,b; Kramer et al., 2006; Marmigere
et al., 2006). For example, Marmigere et al. (2006) reported that
Runx1 is required for the initial stage of the differentiation of
TrkA+ DRG neurons, whereas Chen et al. (2006b) showed that
Runx1 plays a crucial role in the subsequent phenotype transition
from TrkA+ DRG neurons to c-ret+ neurons. Marmigere et al.
(2006) and Chen et al. (2006b) also reported that Runx1 is
involved in the neurite outgrowth and branch formation, and
proper axonal projection to the spinal cord, respectively. In the
present study, to overcome the early embryonic lethality in
Runx1−/− mice, we adopted a new approach by utilizing
transgenic Runx1−/− mice in which liver hematopoietic cells are
selectively rescued by the expression of Runx1 under the control
of the GATA-1 promoter. In these mice, Runx1 is deficient in
presumptive Runx1-expressing cells except liver hematopoieticFig. 1. Rescue of erythropoiesis in Runx1−/− mouse from early embryonic lethality w
plasmid contains the 3.9-kb sequence 5′ of the IE exon, the IE exon itself, the first intro
cDNA. The initiation Met codon in the second exon was replaced by a unique NotI s
E, EcoRI; N, NotI; S, SacI. (B and C) Expression of Runx1 in the liver of E14.5 Runx
of E14.5 Runx1+/+∷Tg (D), but expression is not observed in Runx1−/−∷Tg (E). Sccells. Because of the selective rescue of Runx1 in these
hematopoietic cells, these mice are able to survive until late
embryonic stages. We showed that Runx1 controls the cell
number and cell fate specification of cutaneous DRG neurons and
their axonal projections. Part of the present study has been
published in abstract form (Yoshikawa et al., 2005).Materials and methods
Genotyping and maintenance of animals
The transcription regulatory domain that directs both the primitive and
definitive erythroid cell-specific expression of GATA-1 was identified
previously and referred to as the GATA-1 gene hematopoietic regulatory domain
(G1-HRD) (Onodera et al., 1997). We exploited G1-HRD to rescue Runx1 gene
knockout mice from embryonic lethality by expressing the Runx1 transgene in
erythroid cells specifically (Fig. 1A, Yokomizo et al., in press). Transgenic mice
were generated by microinjection of DNA into fertilized BDF1 eggs using
standard procedures (Wassarman and DePamphilis, 1993). Founders were
screened by PCR, and verified by Southern blot analysis, using a Southern probe
generated from the 4th exon sequence of the Runx1 gene. Mice bearing the
Runx1 germ line mutant allele (Okada et al., 1998) were bred in a clean room
in the Laboratory Animal Resource Center at the University of Tsukuba. Runx1
mutant mice were genotyped as described previously (Okada et al., 1998) and a
pair of primers, RUNT S1 (5′-AGCATGGTGGAGGTACTAGC-3′) and RUNT
AS1 (5′-GGTCGTTGAATCTCGCTACC-3′), was used for Runx1–Tg detec-
tion. Phenotypes of transgenic Runx1−/− mice (Runx1−/−∷Tg) were compared
with the control (Runx1+/+∷Tg) in this study. The present study was approved
by the animal care committee of the University of Tsukuba.
Immunohistochemistry
For cryostat sections, E13.5 whole mouse embryos were immersed overnight
at 4 °C in a fixative containing 4% paraformaldehyde in phosphate-buffered saline
(PBS). Embryos at E14.5 and older were perfused transcardially with the same
fixative and immersed overnight at 4 °C. The thoracic segments (Th) were
dissected and immersed sequentially in 10%, 20% and 30% sucrose solutions in
PBS and frozen in Tissue TekO.C.T. compound (Sakura Finetek Japan). 10- or 12-
μm transverse sections were cut and collected onto MAS-coated glass slides
(Matsunami Glass Ind., Japan), and air-dried for 1 h. If needed, sections were
subjected to heat induced epitope retrieval by heating to 105 °C for 5 min in Dako
REAL™Target Retrieval Solution (Dako). After treatment for 30 min at room
temperature (RT) with 0.3%H2O2 in methanol, the sections were incubated for 1 hith G1-HRD–Runx1–Tg. (A) Structure of the G1-HRD–Runx1 transgene. This
n, and a part of the second exon of the mouseGATA-1 gene in front of the Runx1
ite (shown as N) for subsequent cloning. Restriction enzyme sites are B, BamHI;
1+/+∷Tg (B) and Runx1−/−∷Tg (C). (D and E) Expression of Runx1 in the DRG
ale bars: 50 μm in panels B–E.
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X-100 in PBS. For immunohistochemical analysis, the following antibodies
were used: rabbit anti-RUNX1 (Sigma; 1:1000 dilution), rabbit anti-calcitonin
gene-related peptide (CGRP) (Chemicon; 1:4000), goat anti-CGRP (Biogenesis;
1:4000), rabbit anti-TrkA (a gift from Dr. F. Reichardt; 1:4000), rabbit anti-TrkB
(Upstate; 1:1000), goat anti-TrkC (R&D Systems; 1:2000), rabbit anti-substance
P (Protos Biotech Corporation; 1:2000), rabbit anti-somatostatin (Protos Biotech
Corporation; 1:2000), rabbit anti-calbindin D-28K (Swant; 1:2000), rabbit anti-
VR1 (TRPV1) (Calbiochem; 1:1000), rabbit anti-VRL-1 (TRPV2) (a gift from
Dr. M. Tominaga, and Calbiochem; 1:250), rabbit anti-c-ret (IBL; 1: 50), rabbit
anti-parvalbumin (Swant; 1:2000), rabbit anti-peripherin (Chemicon; 1:2000),
rabbit anti-active-caspase3 (Promega; 1:1000), mouse anti-BrdU (Sigma;
1:1000), mouse anti-Islet-1 (Developmental Studies Hybridoma Bank; 1:100),
mouse anti-Ki67 (BD Biosciences; 1:50), rabbit anti-MAP2 (Chemicon; 1:500),
and goat anti-Lmx1b (Santa Cruz Biotechnology; 1:1000). The sections were
incubated overnight at 4 °C with each of the primary antibodies in the blocking
solution, and then, with a biotinylated secondary antibody for 1 h at RT. The
sections were incubated with the peroxidase conjugated avidin–biotin complex
(Vector Laboratories; 1:100) for 30 min at RT and the positive reactions were
visualized with 3, 3′-diaminobenzidine (DAB) using the ImmunoPure metal
enhanced DAB substrate kit (Pierce). For triple staining, cryostat sections were
incubated with anti-Islet-1 antibody, followed by the incubation with
biotinylated horse anti-mouse IgG (Vector Laboratories; 1:500) and Pacific
Blue conjugated Streptavidin. All the sections were then incubated with rabbit-
or goat-anti-CGRP antibodies, followed by Alexa Fluor 488-labeled donkey
anti-rabbit IgG or Alexa Fluor 594-labeled donkey anti-goat IgG (Invitrogen;
1:500), respectively. Subsequently, the sections were incubated either with anti-
TrkB, substance P, somatostatin, calbindin D-28K, TRPV1, TRPV2, c-ret,
TrkC, parvalbumin or active-caspase3, followed by Alexa Fluor 488-labeled
donkey anti-rabbit IgG or Alexa Fluor 594-labeled donkey anti-goat IgG. Both
Runx1−/−∷Tg and Runx1+/+∷Tg of the same littermates were processed
simultaneously during the immunohistochemical processes.
Cell counting
For counts of CGRP+, TrkA+ and Islet-1+ DRG neurons, the 10th thoracic
segment (Th10)–Th12 DRGs at E17.5 were serially sectioned at 10 μm. The
total number of immunoreactive neurons was counted from the level-matched
thoracic DRGs of each genotype (6 DRGs from 3 embryos were examined). For
cell counting of TrkB, substance P, somatostatin, calbindin D-28K, TRPV1,
TRPV2, c-ret, TrkC and parvalbumin positive cells, 3–7 sections from each
Runx1+/+∷Tg (14 sections from 3 embryos for each antibody) and Runx1−/−∷Tg
(14 sections from 3 embryos for each antibody) were counted at identical
thoracic segments. We first estimated the ratio of DRG neurons that were
immunoreactive for these markers among Islet-1+ DRG neurons in double
stained sections, and then calculated the total number of these neurons based on
the total number of Islet-1+ DRG neurons in each DRG. About 1800–2500
Islet-1+ DRG neurons were examined for the analysis of each marker.
Furthermore, we estimated the ratio of CGRP+ DRG neurons/DRG neurons
immunoreactive for a given antigen (TrkA, TrkB, substance P, somatostatin,
calbindin D-28K, TRPV1, TRPV2, c-ret, TrkC, and parvalbumin). In this anal-
ysis, we examined 161–1613 DRG neurons, depending on the markers (e.g., 161
parvalbumin-immunoreactive DRG neurons and 1613 TrkA-immunoreactive
DRG neurons). In addition, active-caspase3-positive neurons in 8 sections from
each Runx1+/+∷Tg (24 sections from 3 embryos) and each Runx1−/−∷Tg (24
sections from 3 embryos) were counted. More than 132 active-caspase3-positive
neurons amongmore than 4111 Islet-1+ DRGneuronswere counted in E13.5DRG
of each Runx1+/+∷Tg and Runx1−/−∷Tg, and more than 37 active-caspase3-
positive neurons among more than 6882 Islet-1+ DRG neurons were counted in
E17.5 DRG of each Runx1+/+∷Tg and Runx1−/−∷Tg. For cell counting, only the
immunoreactive neurons containing a distinct cell nucleus were counted.
Measurement of DRG volume
Using the serial sections (10 μm thickness) containing whole Th12 DRGs at
E17.5, the areas of DRG in each section were measured and the DRG volume
was calculated using the AxioVision imaging software (Carl Zeiss).BrdU labeling and detection by immunohistochemistry
At E11.5, E12.5 and E16.5, a single intraperitoneal injection of BrdU (5mg/ml
solution in PBS and 60 μg/g of body weight) was performed in pregnant mice
derived from timed mating. After 24 or 48 h, the injected mice were deeply
anesthetized, and embryoswere removed and genotyped. Cryostat sections (10μm
thickness) of Th13 DRG were made as described above, and incubated with anti-
BrdU and anti-peripherin antibodies, followed byAlexa Fluor 594-labeled donkey
anti-mouse IgG and Alexa Fluor 488-labeled donkey anti-rabbit IgG (Invitrogen;
1:500). BrdU-labeled neurons in 8 sections fromRunx1+/+∷Tg (24 sections from 3
embryos) and Runx1−/−∷Tg (24 sections from 3 embryos) were counted. More
than 920 BrdU-labeled neurons among more than 5300 peripherin-positive DRG
neurons were counted in each group.
Statistical analysis
All quantitative analyses were performed on 3 pairs of embryos from 3
independent pregnant mice. Statistical analyses were performed by ANOVA
followed by post hoc analysis (Fisher's Protected Least Significant Difference
Test). Differences were considered significant if the probability of error was less
than 5%. All results were expressed as the mean±SEM.
Results
Rescue of Runx1−/−∷Tg mice by the G1-HRD–Runx1
transgene
Runx1 knockout mice die of impaired fetal hematopoiesis by
E12.5 (Okuda et al., 1996; Wang et al., 1996). This early
lethality has prevented the examination of the roles of Runx1 in
neural development during late embryonic and postnatal stages.
In the present study, we utilized transgenic Runx1−/− mice
(Runx1−/−∷Tg), in which GATA-1+ hematopoietic cells are
rescued by the G1-HRD-regulated expression of Runx1 (Fig.
1A, Yokomizo et al., in press). At E12.5, massive hemorrhag-
ing was observed in the head of Runx1−/− mice, whereas
Runx1−/−∷Tg were viable and showed no such defects
(Yokomizo et al., in press, data not shown). Immunohisto-
chemical examination revealed that Runx1 was expressed in
hematopoietic cells in the liver at E14.5 in both Runx1+/+∷Tg
and Runx1−/−∷Tg (Figs. 1B, C), whereas Runx1 was expressed
in DRG neurons of Runx1+/+∷Tg, but not in Runx1−/−∷Tg
(Figs. 1D, E). The transgenic expression of Runx1 in hema-
topoietic cells allowed these animals to survive until
E18.5. Runx1+/+∷Tg and Runx1+/−∷Tg were born at E19.5,
but Runx1−/−∷Tg were seldom born viable. At E17.5,
Runx1−/−∷Tg were often viable, but showed the hemorrhaging
in the brain, subarachnoid space and subcutaneous area,
probably because of the impaired blood vessel formation.
Because this bleedingwasmostly localized in the head and upper
trunk region, but not in the lower trunk region (Supplementary
Fig. 1), we examined lower thoracic regions in the present study.
Increased number of DRG neurons in Runx1−/−∷Tg
At E17.5, Runx1−/−∷TgDRGs were enlarged compared with
those of Runx1+/+∷Tg (Figs. 2A, B). The volume of the Th12
DRG in Runx1−/−∷Tg (0.0363±0.0022 mm3, 6 DRGs from 3
embryos) was 1.29-fold greater than that in Runx1+/+∷Tg
(0.0281±0.0030 mm3, 6 DRGs from 3 embryos; p<0.05) (Fig.
Fig. 2. The DRG neuronal number and the DRG volume are increased in E17.5 Runx1−/−∷Tg. (A and B) Photomicrographs showing the expression of Islet-1
immunoreactivity in the DRG of Runx1+/+∷Tg (A) and Runx1−/−∷Tg (B). (C and D) The volume of the DRGs (C) and the total number of Islet-1+ DRG neurons at the
level of Th12 (D) in Runx1+/+∷Tg (open bar) and Runx1−/−∷Tg (solid bar). n=6 for each group. Data are shown as mean±SEM; *p<0.05, **p<0.001. Scale bars:
100 μm in panels A and B.
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neurons, because the total number of DRG neurons also showed
a 1.18-fold increase in Runx1−/−∷Tg (9477±279, 6 DRGs from
3 embryos) over that of Runx1+/+∷Tg (8028±145, 6 DRGs
from 3 embryos) (p<0.001) (Fig. 2D).
To clarify whether the increase in the number of DRG
neurons is induced by the excess proliferation of DRG
progenitors and/or defective apoptosis of DRG neurons, the
proliferation of DRG neuron progenitors was examined by
injecting BrdU intraperitoneally into pregnant mice at E11.5 or
E12.5, around the period of peak mitosis of DRG progenitors
(Lawson and Biscoe, 1979). Thereafter, we examined the BrdU-
labeling at E13.5, because Runx1 is not expressed in DRG until
E12.5 (Chen et al., 2006b, data not shown). When we injected
BrdU at E11.5 and examined the BrdU-labeled DRG neurons at
E13.5, the ratio of BrdU+ DRG neurons per peripherin+ DRG
neurons was increased in Runx1−/−∷Tg (17.26±0.93%)
compared to that of Runx1+/+∷Tg (15.03±0.59%) (p<0.05)
(Figs. 3A–C). In contrast, when we injected BrdU at E12.5 and
examined the labeled neurons at E13.5, there was no
significant difference in the ratio of BrdU+ DRG neurons
between Runx1+/+∷Tg and Runx1−/−∷Tg (Runx1+/+∷Tg,
9.15±1.24%; Runx1−/−∷Tg, 8.25±0.54 %; p=0.52). Injected
with BrdU at E16.5, when the mitosis of wild-type DRG
neurons has ceased, virtually no BrdU+ neurons were observed
in both Runx1+/+∷Tg and Runx1−/−∷Tg at E17.5, suggesting
that the loss of Runx1 does not induce mitosis in post-mitotic
DRG neurons (data not shown). Next, we double-stained E12.5
and E13.5 Runx1+/+ DRGs with Runx1 antibody and Ki67
antibody to examine the presence of Runx1 in DRG progenitor
cells. None of the Ki67-immunoreactive progenitors expressed
Runx1 (Figs. 3D–F), confirming the results of previous reports
showing that Runx1 is expressed in postmitotic DRG neurons
(Chen et al., 2006b, Marmigere et al., 2006). These results
suggest that the up-regulation of proliferation in Runx1−/−∷Tg
DRGs may not be cell-autonomous, but mediated indirectly
(e.g. by Runx1-expressing postmitotic DRG neurons or
peripheral tissues). Collectively, results suggest that Runx1
inactivation may promote the proliferation of DRG progenitor
cells in a non-cell autonomous manner.We examined the effects of Runx1-deficiency on the
apoptosis of DRG neurons. At E13.5, during the peak of the
programmed cell death in the mouse embryonic DRG (White
et al., 1996, 1998), the percentage of caspase3-immunoreac-
tive apoptotic cells showed a significant decrease in the
DRG of Runx1−/−∷Tg (2.46±0.28%) as compared to that of
Runx1+/+∷Tg (3.68±0.54%) (p<0.05, 24 sections from 3
embryos, for each group) (Figs. 3G–I), suggesting that Runx1
inactivation may suppress the apoptosis of DRG neurons.
Unexpectedly, at E17.5, the percentage of apoptotic cells in
Runx1−/−∷Tg DRG was increased by 3.1-fold over that of
Runx1+/+∷Tg, although the percentage of apoptotic cells was
much lower than that observed at earlier stages (Runx1+/+∷Tg,
0.60±0.13%; Runx1−/−∷Tg, 1.85±0.21%; p<0.0001) (Figs.
3J–L). This increase of apoptosis at late embryonic stages
may be caused by mismatch between the increased number
of DRG neurons and the limited amount of their targets
(see below).
In summary, our results suggest that the promotion of pro-
liferation of DRG progenitors and the suppression of apoptosis
of DRG neurons by Runx1 deficiency may be responsible for
the increase of DRG neurons in Runx1−/−∷Tg.
Changes of the cell fate specification in Runx1−/−∷Tg
In order to determine whether the increase of the neuronal
number occurs in a selected population of DRG neurons in
Runx1−/−∷Tg, we examined the differentiation of DRG neurons
by immunohistochemistry using a variety of markers for DRG
neuron subtypes. First, we counted the number of DRG neurons
that were immunoreactive for TrkA and CGRP, two major
markers for cutaneous neurons (Hunt et al., 1992; Ju et al.,
1987; Lawson, 1992). At E17.5, an increased number of TrkA+
DRG neurons were observed in Runx1−/−∷Tg compared with
that of Runx1+/+∷Tg. The total number of TrkA+ neurons in
the Th11 DRG was increased by 1.43-fold in Runx1−/−∷Tg
(6608±224, 6 DRGs from 3 embryos) compared with that of
Runx1+/+∷Tg (4634±116, 6 DRGs from 3 embryos)
(p<0.0001) (Figs. 4A, B, E). Concomitantly, the total number
of CGRP+ neurons in the Th10 DRG was greatly increased by
Fig. 3. DRG increased proliferative activity, but decreased apoptosis in E13.5 Runx1−/−∷Tg. (A and B) BrdU+ neurons in the DRG of Runx1+/+∷Tg (A) and
Runx1−/−∷Tg (B) which received BrdU at E11.5 and were sacrificed at E13.5. Arrows indicated examples of BrdU+ neurons. (C) Quantitative analysis of the
number of BrdU+ neurons in E13.5 Runx1+/+∷Tg and Runx1−/−∷Tg DRG. (D–F) Detection of Runx1+ (red)/Ki67+ (green) in the DRG of E13.5 Runx1+/+∷Tg.
(G and H) Immunohistochemical detection of caspase3 in E13.5 Runx1+/+∷Tg (G) and Runx1−/−∷Tg (H) DRG neurons. (I) At E13.5, the percentage of caspase3+
neurons showed a slight decrease in cell death in the DRG of Runx1−/−∷Tg. (J and K) Caspase3 expression in E17.5 Runx1+/+∷Tg (J) and Runx1−/−∷Tg (K)
DRG neurons. (L) At E17.5, the percentage of cell death in the DRG of Runx1−/−∷Tg was increased. Data are shown as mean±SEM; *p<0.05, **p<0.001. Scale
bars: 50 μm in panels A, B, D, E, F, G, H; 100 μm in panels J and K.
667M. Yoshikawa et al. / Developmental Biology 303 (2007) 663–6742.74-fold in Runx1−/−∷Tg (2454±50) compared with that of
Runx1+/+∷Tg (894±40, 6 DRGs from 3 embryos for each
group) (p<0.0001) (Figs. 4C–E). The increase of both TrkA+
DRG neurons and CGRP+ DRG neurons was also observed at
E16.5 (TrkA+ neurons: 2919 in Runx1+/+∷Tg and 4478 in
Runx1−/−∷Tg; CGRP+ neurons: 678 in Runx1+/+∷Tg and 1431
in Runx1−/−∷Tg, 2 DRGs from 1 embryo for each group).
In order to examine in more detail the effects of Runx1
deficiency in the cell fate specification, E17.5 DRG neurons at
the level of Th6–8 were triple-stained with antibodies against
neurotrophin receptors (TrkB, TrkC, c-ret), neuropeptides
(substance P, somatostatin), calcium binding proteins (calbindin
D-28K, parvalbumin), and TRP channels (TRPV1, TRPV2) in
combination with anti-Islet-1 and anti-CGRP antibodies. TrkC
and parvalbumin are markers for proprioceptive DRG neurons,
and were used for comparison with cutaneous DRG markers.
We first estimated the ratio of DRG neurons that were
immunoreactive for these markers among Islet-1+ DRG neurons
in selected sections (14 sections from 3 embryos), and then
calculated the total number of these neurons based on the total
number of Islet-1+ DRG neurons in each DRG (Fig. 4F).
Somatostatin+ DRG neurons were increased by 1.81-fold
(p<0.005) in Runx1−/−∷Tg (1446±186) compared with that
of Runx1+/+∷Tg (799±94). Among the somatostatin+ DRG
neurons, the number of neurons expressing a low level of
somatostatin was increased from 666± 82 (Runx1+/+∷Tg) to
1297±178 (Runx1−/−∷Tg) (p<0.005). In contrast, c-ret-immunoreactive neurons were greatly decreased by 0.49-fold
(p<0.005) in Runx1−/−∷Tg (967±102) compared with that of
Runx1+/+∷Tg (1962±154). Unexpectedly, TrkC+ DRG neu-
rons were increased by 1.48-fold (Runx1+/+∷Tg, 1023±101;
Runx1−/−∷Tg, 1509±95; p<0.005). No significant differ-
ences were observed in the number of DRG neurons
immunoreactive for TrkB, substance P, calbindin D-28K,
TRPV1, TRPV2, and parvalbumin (Fig. 4F). The number of
TRPV1+ DRG neurons was similar between Runx1+/+∷Tg
(1797±206) and Runx1−/−∷Tg (1672±191), but the
number of DRG neurons expressing a high level of TRPV1
was decreased from 1114± 133 (Runx1+/+∷Tg) to 456±57
(Runx1−/−∷Tg) (p<0.001). These results suggest that the
Runx1 deficiency affected the cell fate of DRG neurons
characterized by the expression of specific biochemical
markers.
Ectopic expression of CGRP in Runx1−/−∷Tg
As described above, the total number of CGRP+ DRG
neurons was greatly increased in E17.5 Runx1−/−∷Tg. Then
we examined the subtypes of DRG neurons that contributed to
this increase of CGRP expression. We stained DRG neurons
using antibodies against TrkA, TrkB, TrkC, substance P,
somatostatin, calbindin D-28K, parvalbumin, TRPV1, TRPV2
or c-ret in combination with CGRP antibody (Fig. 5). Then, we
estimated the ratio of CGRP+ DRG neurons/DRG neurons
Fig. 4. Cell-type-specific changes in the number of DRG neurons in Runx1−/−∷Tg at E17.5. (A–D) The expression of TrkA (A, B) and CGRP (C, D) in Runx1+/+∷Tg
(A, C) and Runx1−/−∷Tg (B, D). (E) Quantitative analysis of the total number of CGRP+ DRG neurons at Th10 and TrkA+ DRG neurons at Th11. n=6 for each group.
(F) The total number of DRG neurons that express the various neuronal markers. Somatostatin+ and TrkC+ DRG neurons are increased in Runx1−/−∷Tg, whereas c-ret+
neurons are decreased in Runx1−/−∷Tg. Data are shown as mean±SEM; *p<0.005, **p<0.0001. Scale bars: 100 μm in panels A–D.
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differentially regulated among the DRG neuron subtypes in
wild type mice. For example, more than 60% of substance P+
neurons expressed CGRP, while less than 20% of TrkC+
neurons expressed this neuropeptide. In Runx1−/−∷Tg, the
ratio of CGRP-expressing neurons increased in all subtypes
examined. For example, 18% of TrkA+ DRG neurons co-
expressed CGRP in Runx1+/+∷Tg, whereas 76% of TrkA+
DRG neurons co-expressed CGRP in Runx1−/−∷Tg. The higher
rate of co-expression with CGRP and TrkA in Runx1−/−∷Tg
compared with the results in Fig. 4E may be due to a higher
sensitivity of the immunofluorescence method over that of the
DAB method. These results suggest that CGRP expression may
be suppressed directly or indirectly by Runx1 in DRG neurons
that express TrkA, TrkB, TrkC, substance P, somatostatin,
calbindin D-28K, parvalbumin, TRPV1, TRPV2 or c-ret.Changes in the central and peripheral projection patterns of
DRG neurons in Runx1−/−∷Tg
We examined the axonal projections of DRG neurons
toward central and peripheral targets. In Runx1+/+∷Tg,
CGRP+ neurons appeared in the DRG by E14.5 and increased
thereafter (Figs. 6A, C). CGRP+ DRG axons entered the spinal
cord by E15.5, and penetrated the dorsal horn by E16.5 (Figs.
6E, G). In accordance with the increase of the CGRP+ DRG
neurons (Figs. 4 and 6B, D), a more dense projection of
CGRP+ axons was detected at E15.5 in Runx1−/−∷Tg
compared with that Runx1+/+∷Tg (Figs. 6E, F). The increase
of CGRP+ axons was apparent by E17.5, as more CGRP+
axons were distributed in a wider range of laminae of the dorsal
horn in Runx1−/−∷Tg (Figs. 6I, J). CGRP was co-localized in
most of the TrkA+ axons in Runx1−/−∷Tg, while CGRP+ DRG
Fig. 5. Increase of co-expression with CGRP in Runx1−/−∷Tg DRG at E17.5. (A1–J1, A2–J2) Double staining of TrkA (A1, A2), TrkB (B1, B2), substance P (C1,
C2), somatostatin (D1, D2), calbindin D-28K (E1, E2), TRPV1 (F1, F2), TRPV2 (G1, G2), c-ret (H1, H2), TrkC (I1, I2) and parvalbumin (J1, J2) in combination with
CGRP in the DRG of Runx1+/+∷Tg (A1, B1, C1, D1, E1, F1, G1, H1, I1, J1) and Runx1−/−∷Tg (A2, B2, C2, D2, E2, F2, G2, H2, I2, J2) DRG neuron at E17.5.
(A3–J3) The ratio of CGRP+ DRG neurons/DRG neurons immunoreactive for a given antigen in Runx1−/−∷Tg DRG are increased compared with Runx1+/+∷Tg at
E17.5 (A3, B3, C3, D3, E3, F3, G3, H3, I3, J3). SP: substance P, SOM: somatostatin, CB: calbindin D-28K, PV: parvalbumin. Data are shown as mean±SEM;
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Scale bars: 50 μm in panels A1–J1 and A2–J2.
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horn in Runx1+/+∷Tg (Figs. 6K, L). Double staining with
MAP2 or Lmx1b antibodies and CGRP antibody revealed that
CGRP+ DRG axons were distributed in laminae I and II in
Runx1−/−∷Tg, whereas these axons were localized in the
superficial layer in Runx1+/+∷Tg (Figs. 6O–R) (Ding et al.,
2004). Similar ventral expansion of axonal projections was
observed in somatostatin+ axons in Runx1−/−∷Tg (Figs. 6M,
N). In addition, MAP2 staining showed that the laminar pattern
of dorsal horn neurons was not affected by Runx1-deficiency
(Figs. 6O, P).
The expression of TrkA and CGRP was also up-regulated
in peripheral DRG axons of Runx1-deficient animals. In the
dorsal skin of Runx1+/+∷Tg at E17.5, TrkA+ DRG axons and
CGRP+ axons were detected in the dermis and the base of the
epidermis as thick fiber bundles (Fig. 7). In Runx1−/−∷Tg,
TrkA+ DRG axons were increased, especially in the dermis,
and most of these axons co-expressed CGRP (Fig. 7). During
the stages examined, neither substance P+ nor somatostatin+axons were observed in the dorsal skin of Runx1+/+∷Tg or
Runx1−/−∷Tg.
Discussion
Rescue of Runx1 expression in hematopoietic cells, but not in
DRG neurons
Runx1−/− embryos die by E12.5 because of impaired fetal
hematopoiesis in the liver (Okuda et al., 1996; Wang et al.,
1996). In order to examine the role of Runx1 in neural
development, Chen et al. (2006b) generated a conditional
Runx1 knockout mice by crossing mice that carry a lox P-based
conditional Runx1 allele and Wnt1-Cre mice that direct Cre
expression in premigratory neural crest cells, including
progenitors of DRG neurons. In these mice, Runx1 function
is selectively impaired in cells of neural crest origin including
DRG neurons. In contrast, we took a different approach to
overcome the early embryonic lethality in Runx1−/− embryos.
Fig. 6. CGRP expression in the DRG and the dorsal horn. (A–D) CGRP+ DRG neurons in Runx1+/+∷Tg (A, C) and Runx1−/−∷Tg (B, D) at E14.5 (A, B) and E15.5
(C, D). (E and F) CGRP+ axons (arrowheads) in the dorsal funiculus of E15.5 Runx1+/+∷Tg (E) and Runx1−/−∷Tg (F). (G–J) CGRP+ axons in the superficial dorsal
horn of Runx1+/+∷Tg (G, I) and Runx1−/−∷Tg (H, J) at E16.5 (G, H) and E17.5 (I, J). (K–R) Double staining of CGRP and TrkA (K, L), somatostatin (M, N), MAP2
(O, P) and Lmx1b (Q, R) in Runx1+/+∷Tg (K, M, O, Q) and Runx1−/−∷Tg (L, N, P, R) at E17.5. Bracket in panels O–R shows laminae I–II. Scale bars: 50 μm in
panels A–D; 100 μm in panels E–R.
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hematopoietic cells are rescued by G1-HRD-regulated expres-
sion of Runx1. Since GATA-1 is expressed only in a limited
number of cell types such as hematopoietic cells and Sertoli
cells in the testis (Burch, 2005), hematopoietic cells in the liver
were rescued in their expression of Runx1, whereas Runx1
expression remained deleted in most other cells such as sensory
ganglia and epidermal appendages (Levanon et al., 2001;
Simeone et al., 1995). These mice survive until late embryonic
stages, and thus, we were able to analyze the roles of Runx1 in
the development of DRGs.Regulation of neuronal number by Runx1
The present study demonstrated that the total number of
DRG neurons was increased in Runx1−/−∷Tg. To elucidate the
mechanisms underlying this increase, we investigated the
effects of cell proliferation and apoptosis. The peak of the
mitosis of DRG progenitors occurs around E11.5 (Lawson and
Biscoe, 1979). When we applied BrdU at E11.5 and examined
the DRG at E13.5, the ratio of BrdU+ DRG neurons was
significantly increased in Runx1−/−∷Tg, suggesting that Runx1
may negatively regulate the proliferation of DRG progenitor
Fig. 7. Both CGRP+ axons and TrkA+ axons are increased in the dermis and the base of epidermis (epi) of Runx1−/−∷Tg. Double staining of CGRP+ axons (A, D) and
TrkA+ axons (B, E) in the dorsal skin of Runx1+/+∷Tg (A–C) and Runx1−/−∷Tg (D–F) at E17.5. Scale bars: 50 μm in panels C and F.
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presumptive postmitotic DRG neurons at E10.5 (Marmigere et
al., 2006) and that Runx1 is first expressed in TrkA+ postmitotic
DRG neurons at E12.5 (Chen et al., 2006a,b). Our results also
showed that Runx1 was not expressed in proliferating DRG
progenitors. These findings suggest that the effects of Runx1
deficiency on the proliferation of DRG progenitors may not be
cell-autonomous, but may be mediated indirectly through other
Runx1-expressing cells. Another possibility may be considered
that Runx1 acts as a differentiation factor for DRG neurons to
induce the cell differentiation of the DRG progenitors.
However, this possibility is unlikely because at least TrkA+
DRG neurons differentiate in Runx1−/− mice from the early
embryonic stages (unpublished observation, and Chen et al.,
2006b).
In addition to the increased proliferative activity, a decrease
of apoptosis during the peak apoptotic stages (White et al.,
1996, 1998) may also contribute to the increase in the total
number of DRG neurons in the Runx1−/−∷Tg. The apoptosis
that occurred in the mutant DRG at late embryonic stages
(E17.5) may be caused by the mismatch between the increased
number of DRG neurons and their targets (Oppenheim, 1991).
The present study showed the increase of both the total number
of DRG neurons and the axonal projection of TrkA+ and
CGRP+ axons in the Runx1−/−∷Tg. No apparent changes in the
targets in skin and spinal cord may limit trophic factors to
support the increased DRG neurons. Although the increased
apoptosis may be caused by the Runx1-deficiency, we cannot
exclude the possibility that the apoptosis may be non-specific,
because hemorrhage was often observed at E17.5.
The total number of neurons together with TrkA+ neurons
has been reported to be decreased in the Runx1−/− trigeminal
ganglia (Theriault et al., 2004). Furthermore, in these mutant
ganglia, TUNEL-positive apoptotic cells were increased with
no changes in the mitotic activity, suggesting that changing the
activity of apoptosis but not proliferation induces a decrease oftrigeminal ganglion neurons (Theriault et al., 2004). Together,
these results suggest that Runx1 plays different roles in the
regulation of cell number (proliferation and apoptosis) between
DRGs and trigeminal ganglia. In addition, Runx3−/− mice
showed a decreased number of DRG neurons as compared with
Runx3+/+ mice (Inoue et al., 2002; Shiga et al., unpublished
observation). Although mechanisms remain to be examined,
these results suggest a different role of Runx1 and Runx3 in the
regulation of DRG neuronal number.
Role of Runx1 in the differentiation of cutaneous DRG neurons
Neural crest cells begin to migrate from the neural tube at E9
in mice (Serbedzija et al., 1990). In the course of DRG
formation, cutaneous neurons begin to express TrkA at the
initial stages of the development (Huang and Reichardt, 2001),
and, shortly thereafter, most of these TrkA+ neurons express
Runx1 (Chen et al., 2006b; Marmigere et al., 2006).
Subsequently, during late embryonic and postnatal stages,
some TrkA+ DRG neurons suppress TrkA expression and
induce c-ret (TrkA−/c-ret+ neurons), while other TrkA+ DRG
neurons retain TrkA expression and induce CGRP (TrkA+/
CGRP+/c-ret− neurons) (Molliver et al., 1997). Thus, the switch
for neurotrophin dependence occurs from nerve growth factor
(NGF)-dependent TrkA+ neurons to glial-cell-line-derived
neurotrophic factor (GDNF)-dependent c-ret+ neurons. Recent
loss-of function and gain-of-function studies have elucidated
the significance of Runx1 in the cell fate specification of these
TrkA+ DRG neurons (Chen et al., 2006b; Kramer et al., 2006;
Marmigere et al., 2006). Marmigere et al. (2006) reported that
the loss of Runt activity in chick embryos depletes TrkA
expression in DRG neurons, leading to the neuronal death,
while the ectopic expression of Runx1 specifically induces the
expression of TrkA, but not TrkB nor TrkC, showing that
Runx1 is required for the initial establishment of TrkA+ DRG
neurons. In contrast, Chen et al. (2006b) demonstrated that
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Runx1 marks DRG neurons that change from the initial TrkA+
to TrkA−/c-ret+ phenotype, while the loss of Runx1 expression
marks DRG neurons with the TrkA+/CGRP+/c-ret− phenotype,
suggesting that Runx1 is involved in this phenotype transition.
This possibility was verified by the experimental analyses
showing that Runx1 function is essential for the transition from
TrkA+ to TrkA−/c-ret+ phenotype in a subset of cutaneous DRG
neurons and that Runx1 expression suppresses CGRP expres-
sion (Chen et al., 2006b; Kramer et al., 2006). The current study
using a different transgenic strategy showed that TrkA+ DRG
neurons appeared in Runx1−/− mice and that Runx1-deficiency
increased the total number of TrkA+ and CGRP+ DRG neurons
accompanied with a decrease in c-ret+ DRG neurons at late
embryonic stages. Thus, our results support the findings of the
latter studies that Runx1 may induce c-ret expression and
suppress CGRP expression. The increase of TrkA+ DRG
neurons observed in the present study may be due to an
impaired switch from the TrkA+ to TrkA−/c-ret+ phenotype.
Otherwise, Runx1 may regulate negatively the number of
TrkA+ DRG neurons by way of controlling the proliferation and
apoptosis, as discussed above. Taken together, Runx1 is likely
to play essential roles in the cell specification of nociceptive
DRG neurons by inducing c-ret expression with concomitant
suppression of TrkA and CGRP expression.
CGRP expression in DRG neurons has been reported to be
regulated by various factors including NGF, activin, BMP2,
BMP4, BMP6, and interleukin-1 beta, some of which are
produced by keratinocytes in the skin (Ai et al., 1999; Hall et al.,
2001; Hou et al., 2003; Moqrich et al., 2004; Patel et al., 2000;
Ritter et al., 1991; Watson et al., 1995) Therefore, several
mechanisms may underlie the increase of CGRP+ DRG neurons
observed in Runx1−/−∷Tg in the present study. One possible
mechanism is that Runx1 directly suppresses the CGRP gene
expression and the Runx1-deficiency de-represses CGRP
expression. The other possibility is an indirect mechanism by
which Runx1 may control the responsiveness for NGF, activin,
BMP2, BMP4, BMP6 and other factors. Finally, Runx1
expressing keratinocytes may be influenced by the Runx1-
deficiency to up-regulate CGRP+ DRG neurons through the
various factors described above (Levanon et al., 2001; Lian
et al., 2003).
The expression of other neuropeptides is also controlled by
Runx1 in the nociceptive DRG neurons. Chen et al. (2006b)
reported that the Runx1-deficiency induced a modest increase
of substance P+ DRG neurons in contrast to the marked increase
of CGRP+ neurons, although the ectopic expression of Runx1
did not result in changes in the expression of substance P
(Kramer et al., 2006). The present study showed that
somatostatin+ DRG neurons were increased, whereas SP+
neurons did not show a significant increase. Therefore, in
addition to CGRP, the expression of neuropeptides including
somatostatin may be down-regulated by Runx1.
Furthermore, the present study showed that the number of
DRG neurons expressing a high level of TRPV1 was decreased
in Runx1−/−∷Tg, supporting results of the previous study (Chen
et al., 2006b). Chen et al. (2006b) suggested that Runx1 mayregulate the expression of a variety of proteins critical for
nociceptive function, which was accompanied by the behavioral
defects in nociception. In Runx1−/− mice, many genes that are
expressed in c-ret+/IB4+ neurons, including TRP class ion
channels and ATP-gated P2X3 channels, are completely
eliminated or greatly reduced, whereas others that are
preferentially expressed in TrkA+ neurons, including DTASIC
and MOR, are expanded. It remained to be elucidated the
relationships between TrkA expression and the expression of
other proteins specific for nociceptive DRG neurons, because
the expression of the Trk receptor can specify phenotype of
DRG neurons (Moqrich et al., 2004).
The present study showed that TrkC+ DRG neurons were
affected by Runx1-deficiency. The TrkC+ neurons were
increased in Runx1−/−∷Tg (Fig. 4F), and CGRP expression in
TrkC+ neurons and parvalbumin+ neurons was also increased
(Fig. 5). In addition to these changes, axons of TrkC+ neurons
and parvalbumin+ neurons were more fasciculated and
undulating in the spinal cord (unpublished observation).
Although Runx1 is not expressed in the TrkC+ DRG neurons
(Chen et al., 2006b; Marmigere et al., 2006), subpopulation of
TrkC+ DRG neurons innervate mechanoreceptors (Kirstein and
Farinas, 2002). Therefore, these mechanoreceptive TrkC+ DRG
neurons may be indirectly affected by Runx1-expressing
tissues.
Regulation of neurite outgrowth and axonal projection by
Runx1
In addition to cell fate specification, Runx1 is involved in
the neurite outgrowth and axonal projection of DRG neurons
(Marmigere et al., 2006; Chen et al., 2006b). Marmigere et al.
(2006) have reported that the overexpression of Runx1 in
combination with Neurogenin-2 in neural crest stem cells
promotes neurite outgrowth and branching formation in vitro.
In Runx1−/− mice, DRG axons enter the spinal cord as in the
wild type mice, but a subset of DRG neurons fail to project to
the specific lamina in the dorsal horn (Chen et al., 2006b). In
wild-type adult mice, TrkA+ DRG axons project predomi-
nantly to lamina I and the outer layer of lamina II (IIo) in the
dorsal horn, whereas Ret+ axons, which can also be labeled by
the lectin IB4, project predominantly to the inner layer of
lamina II (IIi) (Molliver et al., 1997; Snider and McMahon,
1998). In the present study of late embryonic stages, we
observed that, in the Runx1−/−∷Tg, axonal projections of
CGRP+ DRG neurons, which normally project to I/IIo,
expanded to IIi, as well as I/IIo. However, we could not
analyze the axonal projection of IB4+ axons because IB4
binding appears in DRG axons after birth. Most of these
CGRP+ axons co-expressed TrkA+, consistent with the
increase of CGRP+ DRG neurons co-expressing TrkA. This
was also the case in the peripheral projection where increased
CGRP+ axons in the skin co-expressed TrkA. Chen et al.
(2006b) showed that the loss of Runx1 function changes the
targeting of the IB4+ axonal projection from lamina IIi to the
superficial laminae I/IIo. In these Runx1−/− mice, CGRP+
axons remain predominantly in laminae I/IIo, as in the wild
673M. Yoshikawa et al. / Developmental Biology 303 (2007) 663–674type. Thus, the projection of IB4+ axons shifted dorsally from
IIi to I/IIo without changes in the CGRP+ axonal projections.
Therefore, there seems to be a discrepancy concerning the
projection of CGRP+ axons to the dorsal horn between the
present and previous study (Chen et al., 2006b). It is likely
that this discrepancy is due to the ages of the mice. It would
be interesting to examine the ventrally expanded projection of
CGRP+ axons during postnatal stages, to determine whether
mis-routed axonal projections are retained or eliminated.
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